Zai Lab Ltd (NASDAQ:ZLAB) – Investment analysts at Svb Leerink cut their FY2019 earnings per share (EPS) estimates for Zai Lab in a research note issued on Tuesday, June 11th. Svb Leerink analyst J. Chang now forecasts that the company will post earnings per share of ($1.51) for the year, down from their prior forecast of ($1.40). Svb Leerink also issued estimates for Zai Lab’s FY2020 earnings at ($0.42) EPS.
Other equities analysts also recently issued research reports about the company. Zacks Investment Research raised Zai Lab from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a research report on Saturday, May 11th. BidaskClub raised Zai Lab from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. Finally, Leerink Swann set a $46.00 price target on Zai Lab and gave the stock a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Zai Lab currently has a consensus rating of “Buy” and a consensus price target of $36.90.
Zai Lab stock opened at $31.20 on Friday. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -11.82 and a beta of 0.96. Zai Lab has a fifty-two week low of $14.29 and a fifty-two week high of $33.86.
Large investors have recently made changes to their positions in the company. Citigroup Inc. purchased a new stake in Zai Lab during the first quarter valued at about $40,000. Barclays PLC acquired a new position in shares of Zai Lab during the fourth quarter worth about $65,000. Bank of America Corp DE lifted its stake in shares of Zai Lab by 20.3% during the fourth quarter. Bank of America Corp DE now owns 6,528 shares of the company’s stock worth $151,000 after purchasing an additional 1,103 shares in the last quarter. Bank of Montreal Can lifted its stake in shares of Zai Lab by 18.5% during the fourth quarter. Bank of Montreal Can now owns 9,692 shares of the company’s stock worth $225,000 after purchasing an additional 1,512 shares in the last quarter. Finally, Matthews International Capital Management LLC acquired a new position in shares of Zai Lab during the fourth quarter worth about $270,000. 36.39% of the stock is owned by institutional investors and hedge funds.
Zai Lab Company Profile
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Featured Article: How Short Selling Works
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.